<?xml version='1.0' encoding='UTF-8'?>
<article doi="10.15252/msb.20177998"><fig id="20061"><title> - Sample heat-map generated from adult vs.</title><label>Figure 1</label><graphic href="https://api.sourcedata.io/file.php?figure_id=20061"/><sd-panel panel_id="64043"> <p>Pathprint analysis was used to analyze adult and child transcriptomes at the pathway level. To minimize intra-group variation and <sd-pretag role="component" id="sdPretag1990068290sme" type="molecule">maximize</sd-pretag> inter-group variation, two filtering criteria were set in the generation of these data: 1) to <sd-pretag role="component" id="sdPretag1063378644sme" type="molecule">maximize</sd-pretag> homogeneity within an age group based on minimizing the standard deviation, a cutoff of SD&lt;0.475 in the Pathprint score was used; 2) to <sd-pretag role="component" id="sdPretag1115526079sme" type="molecule">maximize</sd-pretag> differences between group comparisons using t-tests, Pathprint scores between groups were only included if p&lt;10<sup>-10</sup>. The heatmap above was generated using the pheatmap package.</p> <graphic href="https://api.sourcedata.io/file.php?panel_id=64043"/></sd-panel></fig><fig id="20063"><title> - Comparison of several methods of drug candidate identification.</title><label>Figure 2</label><graphic href="https://api.sourcedata.io/file.php?figure_id=20063"/><sd-panel panel_id="64044"> <p>Five methods of transcriptome analysis / drug <sd-pretag role="component" id="sdPretag1052423723sme" type="molecule">candidate</sd-pretag> identification were compared in their ability to successfully produce drug targets in at least one prior study showing a <sd-pretag category="assay" id="sdPretag1787221836sme">survival</sd-pretag> benefit from sepsis. 1) Pathprint-<sd-pretag category="assay" id="sdPretag920139451sme">PDN</sd-pretag>: Comparison of pathways by Pathprint and drug <sd-pretag role="component" id="sdPretag246895359sme" type="molecule">candidate</sd-pretag> analysis by pathway-drug network (<sd-pretag category="assay" id="sdPretag1519575439sme">PDN</sd-pretag>); 2) <sd-pretag role="component" id="sdPretag814059852sme" type="cell">DEGs</sd-pretag>-<sd-pretag role="component" id="sdPretag1760397076sme" type="geneprod">PDN</sd-pretag>: Comparison of differentially expressed genes (<sd-pretag role="component" id="sdPretag1627063330sme" type="cell">DEGs</sd-pretag>) by standard methods and drug <sd-pretag role="assayed" id="sdPretag758828966sme" type="molecule">candidate</sd-pretag> analysis by <sd-pretag role="component" id="sdPretag488569447sme" type="geneprod">PDN</sd-pretag>; 3) Random: Drugs chosen at random from the CMap database; 4) <sd-pretag role="component" id="sdPretag1563587943sme" type="cell">DEGs</sd-pretag>-LINCS: Comparison of <sd-pretag role="component" id="sdPretag60946947sme" type="cell">DEGs</sd-pretag> generated by standard methods and drug <sd-pretag role="assayed" id="sdPretag889433856sme" type="molecule">candidate</sd-pretag> analysis using LINCS database and 5) BarCode-LINCS: Comparison of <sd-pretag role="component" id="sdPretag763294052sme" type="cell">DEGs</sd-pretag> generated by BarCode method and drug <sd-pretag role="component" id="sdPretag1673474562sme" type="molecule">candidate</sd-pretag> analysis using LINCS database. The three gene-level methods were found to be no better at generating positive drugs than picking drugs at random. All methods produced significantly lower percent positive rates than the Pathprint-<sd-pretag role="intervention" id="sdPretag1632922315sme" type="geneprod">PDN</sd-pretag> method (p&lt;0.02). Prism software (GraphPad) was used to compare the frequency of prior studies showing benefit for drug leads Fisher"s exact tests</p> <graphic href="https://api.sourcedata.io/file.php?panel_id=64044"/></sd-panel></fig><fig id="20065"><title> - Validation of select PDN drug candidates in an in vivo endotoxemia model.</title><label>Figure 3</label><graphic href="https://api.sourcedata.io/file.php?figure_id=20065"/><sd-panel panel_id="64045"> <p>Therapeutic leads generated using PDN were directly tested for <sd-tag id="sdTag10" source="sdapi" category="assay" entity_type="None" role="None" text="survival" ext_ids="OBI_0000789" ext_dbs="" in_caption="True" ext_names="survival rate" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ontobee.org/ontology/OBI?iri=http://purl.obolibrary.org/obo/">survival</sd-tag> benefit using a <sd-tag id="sdTag1" source="sdapi" category="None" entity_type="organism" role="assayed" text="murine" ext_ids="10090" ext_dbs="" in_caption="True" ext_names="Mus musculus" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ncbi.nlm.nih.gov/taxonomy/">murine</sd-tag> model of <sd-tag id="sdTag22" source="sdapi" category="disease" entity_type="None" role="None" text="endotoxemia" ext_ids="" ext_dbs="" in_caption="True" ext_names="" ext_tax_ids="" ext_tax_names="" ext_urls="">endotoxemia</sd-tag>. Select compounds were injected 24 hours before and on the day of <sd-tag id="sdTag2" source="sdapi" category="None" entity_type="molecule" role="component" text="LPS" ext_ids="CHEBI:16412" ext_dbs="" in_caption="True" ext_names="lipopolysaccharide" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=">LPS</sd-tag> administration, using routes and doses specified in the methods. C57bl/6 female <sd-tag id="sdTag3" source="sdapi" category="None" entity_type="organism" role="assayed" text="mice" ext_ids="10090" ext_dbs="" in_caption="True" ext_names="Mus musculus" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ncbi.nlm.nih.gov/taxonomy/">mice</sd-tag> were injected with a high-lethality dose of <em><sd-tag id="sdTag21" source="sdapi" category="None" entity_type="organism" role="component" text="E. coli" ext_ids="562" ext_dbs="" in_caption="True" ext_names="Escherichia coli" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ncbi.nlm.nih.gov/taxonomy/">E. coli</sd-tag></em> <sd-tag id="sdTag4" source="sdapi" category="None" entity_type="molecule" role="component" text="LPS" ext_ids="CHEBI:16412" ext_dbs="" in_caption="True" ext_names="lipopolysaccharide" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=">LPS</sd-tag> (38-40 Î¼g/g) followed by a subcutaneous injection of sterile saline. Significant differences in concentration between drug and vehicle-treated pre- and post-pubertal <sd-tag id="sdTag5" source="sdapi" category="None" entity_type="organism" role="assayed" text="mice" ext_ids="10090" ext_dbs="" in_caption="True" ext_names="Mus musculus" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ncbi.nlm.nih.gov/taxonomy/">mice</sd-tag> are labeled with **** (p&lt;0.0001), *** (p&lt;0.001, ** (p&lt;0.01), or * (p&lt;0.05). Percent <sd-tag id="sdTag8" source="sdapi" category="assay" entity_type="None" role="None" text="survival" ext_ids="OBI_0000789" ext_dbs="" in_caption="True" ext_names="survival rate" ext_tax_ids="" ext_tax_names="" ext_urls="http://www.ontobee.org/ontology/OBI?iri=http://purl.obolibrary.org/obo/">survival</sd-tag> was compared using a log rank Mantel Cox test</p> <graphic href="https://api.sourcedata.io/file.php?panel_id=64045"/></sd-panel></fig><fig id="20066"><title> - Summary Workflow.</title><label>Figure 4</label><graphic href="https://api.sourcedata.io/file.php?figure_id=20066"/><sd-panel panel_id="64046"> <p>We began by identifying publicly available <sd-pretag role="component" id="sdPretag809378591sme" type="tissue">datasets</sd-pretag> from transcriptome profiling experiments that analyzed <sd-pretag role="component" id="sdPretag1628836012sme" type="tissue">blood</sd-pretag> <sd-pretag role="component" id="sdPretag2017281931sme" type="cell">leukocyte</sd-pretag> samples from adult and child sepsis <sd-pretag role="component" id="sdPretag1746899053sme" type="organism">patients</sd-pretag>. After data processing, we used <sd-pretag role="intervention" id="sdPretag2030788950sme" type="geneprod">Pathprint</sd-pretag> to translate these gene expression patterns to the pathway activity level. By comparing samples at the pathway level the <sd-pretag role="intervention" id="sdPretag2110058268sme" type="geneprod">Pathprint</sd-pretag> method is robust to batch effect and allows for comparison across multiple array platforms. After identifying age-associated differences in pathway activity, we used them to facilitate drug discovery by constructing targeted Pathway Drug Networks (<sd-pretag role="component" id="sdPretag255318999sme" type="cell">PDNs</sd-pretag>). This novel method works by incorporating our target pathways into a base network built upon the correlation in the expression of &gt;16,000 disease, pathway, and drug gene signatures across &gt;50,000 individual <sd-pretag category="assay" id="sdPretag616265928sme">microarrays</sd-pretag>. The resultant network neighborhood was used to identify drugs with positive or negative association with high-<sd-pretag category="assay" id="sdPretag1730859533sme">survival</sd-pretag> (child) or high-mortality (adult) pathways, respectively. We validated top drug <sd-pretag role="component" id="sdPretag1799452045sme" type="tissue">leads</sd-pretag> by curating and analyzing prior data collected in pre-clinical models of sepsis and also by directly testing their ability to improve <sd-pretag category="assay" id="sdPretag1142348939sme">survival</sd-pretag> in a <sd-pretag role="component" id="sdPretag1084778850sme" type="organism">mouse</sd-pretag> model of fatal <sd-pretag id="sdPretag1451763261sd" parent-tag-id="22">endotoxemia</sd-pretag></p> <graphic href="https://api.sourcedata.io/file.php?panel_id=64046"/></sd-panel></fig></article>